News & Events

How the COVID-19 Pandemic Changed KOL Engagement for Pharma Companies

During the early months of the pandemic, convention halls were shuttered. Conferences were canceled as outreach activities rapidly shifted online. Many of us hoped these changes would prove temporary. But 1 year later, it is clear that the pandemic has permanently altered key opinion leader (KOL) outreach. Some companies are still scrambling to catch up.

KOLs remain a valuable resource for clinical and medical insights for pharma companies. It’s time to consider long-term shifts that will enhance your outreach strategy. Virtual communications are here to stay. The right approach can ensure a successful partnership with KOLs through virtual platforms. Read on to learn more.

The Trend Toward Virtual Communications
COVID-19 accelerated existing trends toward virtual meetings and gatherings. As of late 2019, the shift was already underway. Many KOLs withdrew from in-person communications and had begun to rely on virtual engagement. Virtual meetings provided greater control over busy schedules. KOLs also discovered they could be more selective about partnership opportunities. Online communications provided more-diverse offerings and streamlined workflow. Many KOLs had already embraced virtual meetings by the start of the pandemic.

Busy KOLs knew that in-person meetings and travel aren’t always efficient. Some individuals were reluctant to transition their work online. But many quickly discovered the benefits of virtual platforms. A rising number of professionals now report no interest in resuming their pre-pandemic routines. The shift toward virtual communications is likely to be permanent. Some face-to-face meetings may resume. But as we look ahead to 2022, companies should expect to continue virtual outreach.

KOLs Remain a Vital Resource
For pharma companies, KOL engagement remains a high priority. KOLs provide essential guidance on research and marketing endeavors. Strong relationships with KOLs can provide support throughout a product’s life cycle.

The pandemic has touched every industry, and pharma is no exception. Companies urgently need guidance and input from KOLs. These individuals’ on-the-ground insights are tremendously valuable during times of sociocultural change. Investing in KOL outreach now can position your company for success in the coming decades.

If you feel that virtual meetings are a poor substitute for face-to-face contact, you’re not alone. But the right strategy can boost the effectiveness of your virtual outreach efforts.

Tips for Virtual Engagement With KOLs
Integrate Digital Features
Virtual meetings and emails sometimes feel flat. But digital features liven up virtual communication. These tools provide useful information for KOLs.

Consider what features might already be at your fingertips. Your company might have invested in video abstracts, podcasts, infographics, microsites, or polling tools. Deploy these features during KOL outreach to boost engagement.

Be Prompt
KOLs often consider time-management a key benefit of virtual contacts. Busy professionals enjoy skipping traffic, long flights, and lengthy presentations. As they shift toward virtual engagement, they expect your company to fit into their timetable.

Ensure that your representatives show up on time with the relevant materials. End the meeting at the agreed-upon hour. It can be tempting to stretch out virtual meetings. But keep in mind that KOLs are busy. They respect partners who respect their time.

Continue to Use Video Calls
Many companies have grown weary of virtual meetings. However, video chats remain the best way to build lasting relationships with KOLs. They are not a perfect substitute for in-person meetings. But they offer greater warmth and more opportunities for personal connection. Virtual meetings can also serve as private chats or panel discussions. Your company can leverage video calls to build relationships between contacts.

Tell a Story
If your virtual meetings are an endless string of numbers and jargon, it may feel cold. When reaching out to KOLs, soften your message through the use of narratives. Explore the story of your company’s products or research endeavors. Communicate your goals with passion and empathy, and KOLs will respond in kind.

Developing a KOL Engagement Plan
KOL engagement doesn’t happen by accident. Companies need a game plan for accessing KOLs and building lasting relationships.

When creating your strategy, consider the following

  • Anticipate KOL needs. Find out what problems your KOLs are grappling with. Then position yourself as a resource that offers valuable solutions
  • Use an objective-driven approach. Keep your priorities at the forefront of your mind. Find out your KOL’s priorities too. Look for KOLs whose objectives dovetail with your own and nurture these contacts. Rather than connecting with dozens of KOLs, look for a few “perfect fits”
  • Create collaboration opportunities. KOLs are always on the lookout for sponsorships, advisory board positions, and publishing opportunities. Find areas for collaboration. Look for ways to support partnerships between various contacts
  • Embrace feedback. Your KOLs will have a great deal of feedback to share. Encourage open, honest dialogue about your company’s products and services. Take a close look at any critical feedback

Aptitude Health
Building relationships with KOLs can be a challenge. But trusted partner organizations provide immediate virtual access to KOLs. Aptitude Health’s digital platforms improve communication and encourage collaboration. We create connections between life science companies, clinical experts, and community-based physicians. Our hematology-oncology specialists provide your company with expert advice and feedback. Meanwhile, our robust virtual platform makes communication easy. Learn more about our services.

Therapeutic Area

Archives

Matthew Gordon

VP, Real-World Evidence
Matthew has more than 25 years of experience in real-world evidence and observational, non-interventional research. He has led studies across the full life cycle—from startup through publication—supporting objectives that range from understanding a disease’s natural history to fulfilling global safety surveillance requirements. Matthew brings deep expertise in orphan disease programs, having overseen more than 25 long-term, global initiatives, as well as in disease and product registries, prospective pharmacoeconomic studies, and systematic literature reviews. Matthew leads the RWE Registries team, responsible for building the business and team. Prior to joining Aptitude Health, he held senior leadership roles at Parexel, Worldwide Clinical Trials, inVentiv Health Clinical, Quintiles Outcome, and ICON Clinical Research. Matthew holds a BA in sociology from Boston University, is a long-standing member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a frequent speaker at ISPOR, the Center for Business Intelligence, and related industry conferences.

Gerald Stanvitch, PhD

VP, Scientific Content

Cate Browning, PhD

VP, Global Medical Affairs

Erin Zingales Rau

VP, Account Services

Kelly Kocor

VP, People & Culture
Kelly leads both the human resources and talent acquisition teams, ensuring that Aptitude Health attracts, retains, and develops top personnel to drive our continued success. With over 17 years of experience transforming global HR initiatives, Kelly is an expert in harmonizing HR policies and fostering a culture of engagement and partnership. She is committed to partnering with all areas of the business to ensure full regulatory compliance and delivering value-added services to our organization and its people. Kelly is passionate about developing and implementing HR strategies that help support our employees’ professional and personal growth. She is dedicated to fostering a culture that encourages innovation, collaboration, and inclusivity, helping Aptitude Health continue to be a great place to work.

Bart Zygmond

VP, Finance
Bart brings a wealth of experience to the organization, having worked in the life sciences, pharmaceuticals, manufacturing, and service industries. With his expertise in financial reporting, US GAAP, SOX, cash flow modeling, and financial analysis, he plays a crucial role in the company’s financial management and strategy. Prior to joining Aptitude Health as VP, Finance, Bart held several controller positions: at Q2 Solutions, he oversaw the global finance team and financial operations, ensuring the accurate and timely financial reporting of the company. He also held controller positions at Domtar Inc and Veristat.

Eugene Vissers, MD

Senior VP, Global Scientific Content
Eugene is a seasoned medical doctor with over 20 years of international experience in pharma, consultancy, and agency environments. Eugene leads the US team of dedicated experts responsible for developing high-quality medical content. Prior to joining Aptitude Health, Eugene served as medical director at Ipsen and AstraZeneca. With both his medical degree and an MBA, Eugene brings a unique perspective to his role. His clinical background, combined with his business acumen, allows him to develop innovative strategies that drive results. Under Eugene’s leadership, the medical content team delivers scientific information of the highest quality, providing valuable insights to our clients around the world.

Adrian Barfield

VP, US Business Development

Kelley Hernandez

Executive VP, US Business Development
Kelley has over 18 years of experience in the oncology space. Kelley joined Aptitude Health after working with Cardinal Health, where she was part of the Healthcare and Analytics Division, and finished her tenure there with VitalSource™ (GPO division). As the leader of the strategic business development team for the US, Kelley brings a wealth of expertise to the organization. Her experience in the healthcare industry, combined with her ability to identify and capitalize on new business opportunities, is invaluable in driving the company’s growth and success. Kelley’s dedication to building strong relationships with life science partners is a testament to her commitment to delivering exceptional value to the healthcare industry.

Adam Sinensky, MBA

Chief Technology Officer

Adam has over 20 years of experience in the healthcare industry and an MBA in healthcare management. After 10 years as a strategy consultant to life science companies, Adam has spent the last decade as a product and strategy leader focused on bringing technology products to market across the payor, provider, and life sciences segments. By combining his business acumen and experience working directly with software developers, engineers, and data scientists, Adam has successfully led numerous product launches and enhancements from ideation to development and go-to-market initiatives. His product and change management expertise has led organizational shifts from services to technology at companies such as Change Healthcare and Datavant/Ciox. At Aptitude Health, Adam is responsible for growing our portfolio of product offerings by leveraging real-world data and artificial intelligence with our existing solutions and industry-leading Axess Network of healthcare providers. He also oversees our IT and cybersecurity teams.

Stefanie Daniels

Chief Commercial Officer

Stefanie is a seasoned healthcare executive with over 20 years of experience in oncology. She brings a wealth of knowledge and expertise to the organization. Stefanie joined Aptitude Health after spending over a decade as a senior director at Physicians’ Education Resource, an oncology CME vendor. During her tenure, she led and managed teams responsible for grant development/acquisition, program creation/execution, and faculty management. Stefanie’s deep understanding of the oncology industry and her ability to lead teams through complex projects make her a vital part of the organization’s success. Her dedication to providing high-quality solutions to our life science partners is a testament to her commitment to improving cancer patient care.

Jason Cash

Chief Financial Officer

Jason is an accomplished finance professional with over 20 years of experience in the pharmaceutical services industry. Throughout his career, he has demonstrated a keen ability to navigate high-growth organizations, delivering exceptional results. Before joining Aptitude Health, Jason served as the CFO of Veristat International, a global contract research organization. In this role, he led the financial strategy and played a pivotal role in driving the company’s growth and success. Jason’s wealth of experience and expertise in financial management make him an essential member of the leadership team. His strategic thinking and ability to drive results are highly respected within the industry.

Jez Moulding

Chief Executive Officer
Jez is a seasoned leader with over 20 years of experience in general management and regional president roles. He has a proven track record of success in the healthcare industry, having worked in the US, Japan, Australia, Korea, South Africa, France, and the UK for Sanofi, where he supported the launch of 10 new drugs across various therapeutic areas. As chief commercial officer at UDG Healthcare and EVP at Ashfield, Jez demonstrated his expertise in developing and implementing successful business strategies. He joined Aptitude Health from Pharmaspectra, an IQVIA business, where he served as CEO since 2018. Jez’s extensive experience in the pharmaceutical industry and his leadership skills make him an invaluable asset to the organization.
Aptitude Health
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.